Blueprint
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section
13 or 15(d) of
the Securities
Exchange Act of 1934
Date of Report
(Date of earliest event reported): May 7, 2019
AZURRX BIOPHARMA, INC.
(Exact name of
Registrant as specified in its Charter)
|
Delaware
|
001-37853
|
46-4993860
|
|
(State or Other
Jurisdiction of
Incorporation or
Organization)
|
(Commission File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
760 Parkside Avenue
Downstate Biotechnology Incubator,
Suite 304
Brooklyn, New York
|
|
11226
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:(646)
699-7855
(Name, address,
including zip code, and telephone number, including area code, of
agent for service of process)
NOT APPLICABLE
(Former Name or
Former Address, if Changes Since Last Report)
Check the
appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the
following provisions):
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR
240.12b-2) ☒
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act ☐
Securities registered pursuant to Section
12(b) of the Act:
|
Title of Each
Class
|
Trading
Symbol
|
Name of Each
Exchange on Which Registered
|
|
Common stock,
par value $0.0001 per share
|
AZRX
|
Nasdaq Capital
Market
|
Item 7.01. Regulation FD Disclosure.
See
Item 8.01 below.
The information in this Current Report
on Form 8-K, including the information set forth in
Exhibit 99.1, is being furnished and shall not be deemed
“filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the
“Exchange
Act”), nor shall it be
deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a
filing.
Item 8.01. Other Events.
On
May 7, 2019, the Company began using an updated corporate
presentation, a copy of which is attached to this Current Report on
Form 8-K as Exhibit 99.1.
Item 9.01. Financial
Statements and Exhibits.
See
Exhibit Index.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
AzurRx BioPharma, Inc.
|
|
|
|
|
|
|
|
Date: May 7,
2019
|
By:
|
/s/ Johan M.
Spoor
|
|
|
|
|
Name: Johan M. Spoor
|
|
|
|
|
Title: Chief Executive Officer
|
|
Exhibit
Index
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
|
Corporate
Presentation, dated May 2019
|
